Applicability of avidin protein coated mesoporous silica nanoparticles as drug carriers in the lung by Van Rijt, Sabine H. et al.
Nanoscale
PAPER
Cite this: Nanoscale, 2016, 8, 8058
Received 21st June 2015,
Accepted 7th March 2016
DOI: 10.1039/c5nr04119h
www.rsc.org/nanoscale
Applicability of avidin protein coated mesoporous
silica nanoparticles as drug carriers in the lung†
S. H. van Rijt,*‡a D. A. Bölükbas,‡a C. Argyo,b K. Wipplinger,‡a M. Naureen,‡a S. Datz,b
O. Eickelberg,‡a S. Meiners,‡a T. Bein,*b O. Schmid‡a and T. Stoeger‡a
Mesoporous silica nanoparticles (MSNs) exhibit unique drug delivery properties and are thus considered
as promising candidates for next generation nano-medicines. In particular, inhalation into the lungs rep-
resents a direct, non-invasive delivery route for treating lung disease. To assess MSN biocompatibility in
the lung, we investigated the bioresponse of avidin-coated MSNs (MSN-AVI), as well as aminated
(uncoated) MSNs, after direct application into the lungs of mice. We quantified MSN distribution, clearance
rate, cell-specific uptake, and inflammatory responses to MSNs within one week after instillation. We
show that amine-functionalized (MSN-NH2) particles are not taken up by lung epithelial cells, but induced
a prolonged inflammatory response in the lung and macrophage cell death. In contrast, MSN-AVI co-
localized with alveolar epithelial type 1 and type 2 cells in the lung in the absence of sustained inflamma-
tory responses or cell death, and showed preferential epithelial cell uptake in in vitro co-cultures. Further,
MSN-AVI particles demonstrated uniform particle distribution in mouse lungs and slow clearance rates.
Thus, we provide evidence that avidin functionalized MSNs (MSN-AVI) have the potential to serve as versa-
tile biocompatible drug carriers for lung-specific drug delivery.
Introduction
In the past decades, the use of nanoparticles as inert carriers
for therapeutic agents has revolutionized the field of drug
delivery research. Several nanoscale drug delivery systems,
especially non-functionalized particle formulations, have been
approved by the FDA and European Medicines Agency for treat-
ment of cancer.1 Nanocarriers offer major improvements such
as increased bio-availability of the incorporated agent, site
specificity, and the ability to overcome multi-drug resist-
ance.2,3 Particularly, mesoporous silica nanoparticles (MSNs)
are novel drug carriers with unique properties, such as high
loading capacity with tunable pore sizes and volumes for trans-
port of a wide variety of cargo molecules.4 Importantly, these
particles can be selectively functionalized at specific sites
within their structure. For example, the particle core offers a
site for covalent attachment of fluorescent dye molecules for
particle tracking in biological studies.5 In addition, the surface
of the MSNs can be selectively modified to introduce con-
trolled drug release functions for optimized drug delivery.4 For
example, in our recent work we developed mesoporous silica
nanoparticles with protease-responsive avidin caps for control-
lable drug release in lung tumour areas.6 Due to the tight
sealing of the mesopores by the avidin caps and the selective
cleavage of these caps at high protease concentrations found
in lung tumours, these drug carriers were able to efficiently
release a combination of chemotherapeutic drugs in vitro and
ex vivo (mouse and human) with high tumour-selectivity.
Other interesting examples of functionalized MSNs that have
shown in vivo effectiveness include MSNs functionalized with
PEG chains,7 folic acid,8 or transferrin.9 Due to their unique
properties, MSNs have been considered as promising candi-
dates for next generation nano-medicines.10 However, before
these carriers can be used in the clinic, their biocompatibility
needs to be proven. Although MSNs are generally considered
to be biocompatible, several reports suggest that their bio-
response is strongly affected by their size,11 shape,12 porosity,13
and surface chemistry.11,14 In addition, the administration
route has been found to play an important role for their bio-
distribution and bioresponse.15 Encouragingly, in vivo toxicity
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studies on different types of MSNs administered using several
application routes, indicate that the use of these particles is
safe for drug delivery purposes,16–20 however, not many of these
studies deal with the applicability of MSNs directly in the lung.
Direct application of nanoparticles into the lung (i.e. inha-
lation therapy) would be beneficial for treatment of (chronic)
lung diseases such as idiopathic pulmonary fibrosis (IPF),
chronic obstructive pulmonary disease (COPD) and asthma, as
drugs are directly administered in the target organ. This is
advantageous because high local doses at the site of disease
(lung) can be accomplished allowing for high efficacy com-
bined with low prevalence of side effects. Moreover, in contrast
to oral administered delivery, inhaled drugs bypass the gastro-
intestinal tract and the liver, avoiding problems associated
with drug degradation in these organs and/or stability in
blood circulation. Moreover, pulmonary application of drugs
presents a non-invasive route for systemic delivery of drugs,
since the huge surface area of the alveolar lung epithelium
(ca. 100 m2) presents an effective portal of entry into the blood
stream. Many drug delivery materials such as polymers are
commonly accepted as biocompatible for systemic appli-
cations, but some have shown to develop adverse cytotoxic and
pro-inflammatory properties in the lungs and seem therefore
not suited for direct application into the lung.21 Moreover, the
inflammatory potential of nanoparticles is especially relevant
for the treatment of inflammatory lung diseases such as COPD
and asthma, as the additional inflammation caused by drug
delivery particles could lead to worsening of the symptoms.
Here, we investigated the suitability of direct application of
avidin-capped MSNs in the lung, namely their distribution,
clearance rate, cell specific uptake, and the inflammatory
response induced over the course of one-week time. For that
purpose, single high doses (20 or 100 µg per mouse) of avidin-
capped MSNs (MSN-AVI) were instilled in adult BALB/c mice,
and their bioresponse after 1, 3, and 7 days was studied. To
analyse the impact of the avidin protein coating, we also
included non-protein coated MSNs containing propyl amines
on the outer shell (MSN-NH2) in the study. Labelling of the
particle core with a fluorescent dye (ATTO 633) allowed for
whole lung dosimetry as well as cell specific particle tracking
in lung cryo-sections and cytospins of bronchoalveolar lavage
fluid (BALF) recovered cells. Moreover, supporting studies
using in vitro cell cultures were performed. This provided evi-
dence that MSNs capped with avidin are significantly more
biocompatible than amino functionalized MSNs as proven by
analyses of their inflammation and toxicity profiles, biodistri-
bution, and cell specific internalization rates, and thus hold
potential for use in future lung disease therapy.
Materials and methods
Materials
Core–shell functionalized MSNs containing thiol groups in the
core and propyl amines on the shell (MSN-SHinNH2,out), avidin
coated MSNs (MSN-AVI) and outer shell non-functionalised MSN
particles (nonMSN) were synthesized as previously reported.5,6
Characterisation of the MSN-SHinNH2,out, and MSN-AVI can be
found in Fig. S1.† Details on the synthesis and characterization
of non-functionalised MSNs can be found in Fig. S2.†
The MSNs suspended in bi-distilled water feature BET
surface areas of 1150 m2 g−1 (MSN-NH2) and 90 m
2 g−1
(MSN-AVI), zeta-potentials of −30 mV (MSN-NH2) and +30 mV
(MSN-AVI) at pH 7.4, and diameter of 106 ± 9 nm (MSN-NH2)
and 164 ± 15 nm (MSN-AVI). The cores of the MSNs were co-
valently labelled with ATTO 633 dye and the outer surface con-
tained either NH2 groups (MSN-NH2) or avidin protein
(MSN-AVI) covalently attached to the MSNs through a peptide
linker. Further details on the synthesis and characterization of
the MSNs can be found in the ESI.†
Cleaved caspase-3 antibody (Asp175) (Cell signaling, 9661),
T1α antibody (R&D, AF3244), Pro-SPC antibody (Millipore,
AB3786), MAC3 antibody (BD biosciences, BD 550292), were
used as received. Bi-distilled water was obtained from a Milli-
pore system (Milli-Q Academic A10). The mouse cell lines,
MH-S (murine alveolar macrophages), MLE-12 (murine lung
epithelial cells), and CCL-206 (murine lung fibroblasts) were
obtained from ATCC (American Type Culture Collection, Mana-
ssas, USA). The MLE-12 cell line was maintained in RPMI
1640 medium (Gibco, Life Technologies); the MH-S cell line
was maintained in RPMI 1640 medium supplemented with
1 mM Na-pyruvate, 10 mM HEPES, and 50 µM 2-ME (all Appli-
Chem). The CCL-206 cell line was maintained in
DMEM-F12 medium (Gibco, Life Technologies). All media
were supplemented with 10% FBS (Biochrom) and 1% penicil-
lin/streptomycin (Life Technologies). All cells were grown at
37 °C in a sterile humidified atmosphere containing 5% CO2.
Study design
The nanoparticles were instilled into Balb/c mice (20 or
100 µg) and after 1, 3, or 7 days the lungs were excised (n = 10
per group). Characterisation of the MSN dispersion over time
was performed to assess the agglomeration of the nano-
particles in cell culture medium (RPMI supplemented with
FCS). MSN-NH2 particles of 100 nm primary size agglomerated
after 1 hour to form microparticles of about 1 µm, while
MSN-AVI particles agglomerated to a much lesser extent
(Fig. S3A†). It is important to note that the particles were
instilled into the mouse lungs as a homogeneous mixture by
vortexing before application (i.e. minimal agglomeration had
taken place). Four lungs were directly prepared for cryo-slicing.
An additional six mice were used for bronchoalveolar lavage
(BAL); BAL fluid (BALF) was collected and separated into cells
and supernatant by centrifugation. In addition, BAL recovered
cells on cytospins were prepared for all mice for differential
cell count. Furthermore, the lavaged lungs and the BAL were
used for dosimetry analyses (see Fig. S3B† for a scheme of the
experimental set-up).
Methods
MTT assay. The MTT assay was performed to assess cell via-
bility after exposure to the MSNs in vitro. Briefly, 14 × 103
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MLE-12 cells per well and 7 × 103 MH-S or CCL-206 cells per
well were seeded in 96-well plates. 24 h after seeding, cells
were exposed to 10, 50, 100, 250, or 500 µg mL−1 of MSN-NH2
or MSN-AVI particles for 16 h. After treatment, 10 µL of freshly
prepared solution of 5 mg thiazolyl blue tetrazolium bromide
mL−1 PBS (Sigma) was added to each well, and the cells were
incubated at 37 °C for 1 h. The supernatant was then aspi-
rated, and the violet crystals were dissolved in 500 µL isopro-
panol + 0.1% Triton X-100 (both AppliChem). Absorbance was
measured at 570 nm, using a Tristar LB 941 plate-reader (Bert-
hold Technologies). Experiments were done in triplicate. Data
analyses were performed in Prism GraphPad (version 5.0) soft-
ware. All values are shown as mean with standard deviation.
For comparison of two groups, a one-way ANOVA was per-
formed. A p-value lower than 0.05 was considered statistically
significant.
Co-culture experiments. MLE-12 cells were labelled with
VybrantDiD (Thermo Fisher Scientific, Germany) before they
were seeded, according to the procedure described by Bur-
guera et al.22 Briefly, MLE-12 cells were incubated for 20 min
with 5 µL mL−1 of VybrantDiD. The labelled cells were washed
three times with their respective medium and 4 × 105 cells per
well were seeded in 6-well plates and incubated for 12 h. After
incubation, 2 × 105 MH-S cells per well were seeded in the
same 6-well plates and incubated for 4 h. 50 µg mL−1 MSN-AVI
or MSN-NH2 was added to the wells and the plate was incu-
bated for 16 h. The cells were then trypsinised, washed three
times with PBS, and finally suspended in 700 µL of PBS.
Samples were then analysed by flow cytometry (BD LSRII).
MSN uptake in the different cell types was quantified by gating
the labelled MLE-12 cells and non-labelled MH-S cells using
the APC-A channel (Fig. S5†), and analysing the particle signal
(FITC channel) in each gated cell population.
Animal experiments. Animal experiments were carried out
according to the German law of protection of animal life and
were approved by an external review committee for laboratory
animal care. 8–12 week-old female BALB/cAnNCrl mice
(Charles River Laboratories, Sulzfeld, Germany) were intra-
tracheally instilled, as described by Stoeger et al.23 1, 3, or 7 d
post-instillation mice were sacrificed with an overdose of keta-
mine (188.3 mg per kg body weight) and xylazin hydrochloride
solution (4.1 mg per kg body weight) (bela-pharm, Germany)
and their blood was retro-orbitally collected for further investi-
gation. The lungs of 6 mice were lavaged with PBS buffer
(37 °C), as previously described.24 Cytocentrifuged slides of
spun down lavaged cells were prepared for cell differentiation,
after staining with May-Grünwald dye. For each mouse two
slides were used for cell differentiation counting (200 cells per
slide). Two additional sets of BAL cell cytospins were frozen at
−80 °C for subsequent confocal microscopy analyses. Lavaged
lungs were then isolated and frozen for whole lung fluo-
rescence analysis as described below. Four non-lavaged mice
lungs from each group were excised and prepared for cryo-
slicing and immunofluorescent staining.
Cytokine release. In this study, secretions of five cyto-/che-
mokines (IL-1β, TNF-α, CXCL1, CXCL5, and CCL2) were investi-
gated by ELISA analyses performed with the BAL (DuoSet
ELISA, R&D Systems, Inc., Minneapolis, USA). The assay was
performed as previously described.25
Histological preparations. After treatments, four mice from
each group were anesthetised and sacrificed as aforemen-
tioned for histological analyses. Following intubation and dia-
phragm dissection, lungs were perfused via the right ventricle
with sodium chloride solution (Braun Vet Care, Germany).
Airways were filled with Neg-50™ frozen section medium
(Fisher Scientific) at room temperature. Later, the tracheae
were knotted, the lungs were excised and transferred into cryo-
molds (Thermo Scientific) loaded with Neg-50™. Samples were
left to freeze on dry ice and then stored at −80 °C. 14 µm thick
cryo-sections were sliced with the cryostat (Carl Zeiss Hyrax
C 50) and placed on superfrost ultra plus adhesion slides
(Thermo Scientific). Immunofluorescence stainings were per-
formed as described below. For hematoxylin and eosin stain-
ing, the lungs were placed in 4% (w/v) paraformaldehyde and
processed for paraffin embedding. The deparaffinised 3 µm
thick sections were stained with hematoxylin and eosin (both
Carl Roth, Germany) subsequently, and dehydrated respect-
ively in consecutively grading ethanol and xylene solutions
(both AppliChem, Germany). Dried slides were mounted in
entellan (Merck, Germany).
Immunofluorescence analyses. Lung cryo-sections or cytos-
pins of BAL recovered cells were fixed with methanol 70 vol%
solution for 10 min, washed with PBS, blocked with Roti®-
ImmunoBlock (Carl Roth, Germany) for 1 h at room tempera-
ture, and incubated with primary antibody at 4 °C overnight.
Afterwards, lung cryo-sections were washed with PBS, incu-
bated with Alexafluor 488 secondary antibody for 2 h at room
temperature, again washed with PBS and finally stained with
DAPI (Sigma-Aldrich). In case phalloidin staining (Life Techno-
logies) was used, lung cryo-sections were incubated with a
mixture of phalloidin and DAPI for 30 min at room tempera-
ture directly after the fixation and washing step. Stained lung
cryo-sections were mounted using fluorescence mounting
medium (DAKO, USA) and analysed using confocal microscopy
(LSM710, Carl Zeiss, Germany).
Dosimetry. As the core of the MSNs was labelled with ATTO
633, both the BAL fluid and the lavaged lung tissue were ana-
lysed for MSN dosimetry based on quantitative fluorescence
analysis at three time points (1 d, 3 d, 7 d). While aliquots of
the thawed supernatant of the centrifuged BAL could be
sampled directly, an aliquot of the cell pellet of the BAL was
resuspended in 200 µL PBS, vortexed and further diluted with
PBS to yield 1000 µL of sample. The lavaged lung tissue was
homogenized according to the following protocol. A defined
volume of PBS (1200 µL minus liquid content of the lung
approximated by 1 mg of lung tissue corresponding to 1 µL)
was added to the tissue samples. The samples were mechani-
cally homogenized with a high-performance disperser (T10
basic ULTRA-TURRAX®) at room temperature until no tissue
pieces were visible anymore (ca. 3–5 min with short breaks to
avoid undue heating of the samples). Residual tissue was
rinsed off the disperser using 300 μL of PBS. Samples were vor-
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texed immediately prior to pipetting four 50 μL aliquots (quad-
ruple determination) from each of the samples in a black 96-
well plate for quantitative fluorescence analysis with a stan-
dard multiwell plate reader (Tecan Safire 2; bandwidth of
optical filters: 7 nm; excitation and emission wavelength:
630 nm and 650–670 nm (average of 650 nm, 660 nm and
670 nm), respectively). The fluorescence signals were related to
the corresponding MSN mass using standard curves, which
were prepared from the BAL and lung tissue of non-exposed
mice according to the same protocol described above (cage
control).
The dosimetric method presented here was validated using
reference mice with a known pulmonary MSN dose as pre-
viously described.26 In brief, these reference mice received
100 µL of the MSN-AVI suspension via intratracheal instillation
and were sacrificed immediately after the procedure to avoid
dose bias due to partial clearance of the applied MSN-AVI par-
ticles from the lung. The actually instilled volume of the
MSN-AVI suspension was determined for each mouse by gravi-
metric analysis of the instillation wear prior and after instilla-
tion.26 The spectrophotometrically measured amount of
MSN-AVI agreed with the applied amount of MSN-AVI within
the expected experimental uncertainty of 15%. Finally, 7 d-
incubation of MSN-AVI particles in the supernatant of the BAL
and subsequent centrifugation revealed that no detectable
amount of the fluorescent tracer (ATTO 633) was leaking out of
the MSN-AVI. This is a prerequisite for reliable pulmonary
dosimetry based on fluorescence analysis.
Native gel (protein corona). To analyze the difference in
protein corona formation with respect to the different functio-
nalizations, we performed native PAGE after treating the MSNs
with isolated mouse lungs alveolar lining fluid (BALF). 500 µL
of each MSN (-AVI or -NH2 at a concentration of 1 mg mL−1)
was centrifuged at 10 000 rpm and HBBS medium was
removed, the pellet was resuspended in 500 µL mouse BAL.
500 µL of each MSN particle type in HBBS 1 mg mL−1 was
used as control. The samples were incubated at 37 °C for
16 hours while gently shaking. After the incubation period, the
samples were vortexed briefly followed by centrifugation at
18 000 rpm for 40 min at 15 °C. The supernatant was removed
and the remaining pellets were washed with PBS (centrifu-
gation at 18 000 rpm for 40 min at 15 °C after each wash).
Finally, the pellet was dissolved in 50 µL of PBS and run on a
10% native gel for 90 minutes at 100 V. The native gel was
stained with page blue™ and the whole gel was imaged using
a ChemiDoc imaging system (Bio-rad).
Statistics. All values are presented as mean ± standard devi-
ation (SD) of six animals per group (n = 6), unless otherwise
stated. Significant differences between two groups were evalu-
ated by the unpaired two-tailed t-test with Welch’s correction.
Statistical analysis was performed using the program Graph-
Pad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA 92037,
USA). Quantification of nanoparticles in cryo-sections or on
BAL cytospins was conducted using the IMARISx64 software
(version 7.6.4, Bitplane, Switzerland). A p-value lower than 0.05
was considered statistically significant.
Results and discussion
Pulmonary inflammation analyses
In vivo inflammatory cell recruitment into the airspace was
first assessed by BAL differential cell count. Total BAL cell
numbers were not significantly different from sham control
(PBS) at day 1, but increased at day 3 for 100 µg of MSN-AVI
and at day 7 for 100 µg of MSN-NH2 particles (Fig. 1A). These
changes are mainly related to the increases in macrophage
numbers, which in general represent the majority of BAL leu-
kocytes (Fig. 1C). A particular severe inflammatory response
was detected by the acute increase of polymorphonuclear neu-
trophils (PMNs): after 1 day of treatment with the high dose
(100 µg) of MSN-NH2 particles giving rise to 60% of total BAL
cells (Fig. 1B and Table 1). The same treatment with MSN-AVI
particles also resulted in a distinct PMN influx into the air-
space; however, comparatively less pronounced to what was
observed for the MSN-NH2 particles (33% of total BAL cells,
Fig. 1B). This almost 2 fold higher PMN influx into the alveolar
airspace at day 1 after instillation for MSN-NH2 compared to
MSN-AVI particles indicates an improved biocompatibility of
the MSN surface due to avidin capping. In addition, for both
particle types, a time-dependent resolution of the neutrophilic
inflammation was noted, but only for the MSN-AVI particles
inflammation had completely resolved after 7 days (Fig. 1B),
further indicating improved biocompatibility for MSN-AVI.
In line with that, only MSN-NH2 instillation resulted in
macrophage accumulation in the airspace from day 3 to day 7
(Fig. 1C and Table 1) as well as the formation of giant cells
(multinucleated macrophages, Fig. 1D and Table 1), both of
which are signs for chronic inflammation and foreign body
response.27 Lymphocyte numbers remained below 2000
(<0.5% of total BAL cells) for all conditions investigated
(Fig. S3C†).
Inflammation caused by MSN-NH2 was further assessed on
the molecular level by BALF cytokine profiling, assessing IL-1β,
and TNF-α as the major pro-inflammatory master cytokines,
CCL2 as classical monocyte/macrophage and CXCL1 and
CXCL5 as the most relevant neutrophil chemoattractants.
Treatment with MSN-NH2 caused the highest pro-inflamma-
tory cytokine response; 1 day after treatment yielded high
levels of all cytokines investigated (Fig. 1E–I). BALF levels of
the two master cytokines for inflammation, IL-1β and TNFα,
were high during the acute phase after MSN-NH2, but not after
MSN-AVI treatment and returned to baseline levels by day 7
(Fig. 1E and F). Levels of chemokine CCL2, a monocyte attrac-
tant, correlated rather with PMN than macrophage numbers
and were highest 1 day after MSN-NH2 treatment (Fig. 1G),
where the lowest macrophage numbers were detected (Fig. 1C).
This argues for significant macrophage cell death during the
acute phase after MSN-NH2 instillation, causing a depletion of
the alveolar macrophage pool uncompensated by the high
levels of the CCL2 monocyte/macrophage attractant. The con-
centrations of the functional murine IL-8 homologues, CXCL1
and -5 (Fig. 1H and I) correlated well with the number of BAL
PMNs (Fig. 1B) and showed accordingly higher levels for
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MSN-NH2 than MSN-AVI treated lungs. Elevated levels of the
epithelial derived CXCL5 at day 7 could be interpreted as a
sign for prolonged epithelial pro-inflammatory response to
MSN particles, however similar levels are observed for
untreated controls at day 1, thus questioning a physiological
relevance. No evidence for inflammation was detected at the
lower dose of 20 µg MSN-AVI per mouse, suggesting 1 mg
kg−1 as a safe dose for pulmonary applications for this par-
ticle type.
The impact of the particle characteristics, agglomeration
state, zeta-potential and specific surface area are of particular
interest for the development of safe nanocarrier systems for
pulmonary drug delivery. Recently, an indirect correlation
between the agglomerate size of instilled particles and the
Fig. 1 BAL cell analysis and cytokine release in BALF at three time points after MSN instillation into Balb/c mice. Bronchoalveolar lavage (BAL) cells
were counted and dead cells were discriminated by Tryphan blue staining; differentiation was analyzed by May-Grünwald staining. Total BAL cell
count is shown in A, total neutrophil numbers in B, macrophage numbers in C, and multinucleated macrophages in D. Release of cytokines was
measured in bronchoalveolar lavage fluid (BALF) for each animal in each group, interleukin-1 beta (IL-1β) is shown in E, TNF-α is shown in F, mono-
cyte chemotactic protein 1 (CCL2) is shown in G, Cxcl1 is shown in H, and Cxcl5 is shown in I. Values are indicated as mean ± SD, n = 6, asterisks rep-
resent significance compared to PBS control groups (100 µL PBS instilled animals) with ***p < 0.001, **p < 0.01, *p < 0.05. HCC = home cage
control (non-treated animals).
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acute inflammatory response was described for different dis-
persions of nickel-oxide nanoparticles with size distributions
ranging from 100 nm to 4 µm.28 Based on their findings the
authors argued that the reduced biologically accessible surface
area of poorly dispersed suspensions might be limiting the
bioactivity and toxicity of the instillation delivered nano-
particles. High zeta-potential of nanoparticle dispersions are
generally appreciated for their enhanced stability, but have
also been associated with increased toxicity and inflam-
mation.29,30 As opposed to this broad rule, we show an
improved biocompatibility for MSN-AVI preparations character-
ized by low agglomerate size and even higher zeta-potential as
compared to the MSN-NH2 material. The particle surface of
crystalline silica (i.e. quartz), is well known to induce lung
inflammation (silicosis) upon inhalation. Toxicity has also
been shown for some non-crystalline (amorphous) silica par-
ticles when applied directly in the lung, although highly
dependent on size, surface and preparation route of the silica
particles.31 The release of IL-1β from pulmonary macrophages
is described as a central mechanism triggering their toxicity in
the lung.32 In agreement with the latter, the highest levels of
IL-1β release, and inflammatory cell accumulation were
detected for MSN-NH2 particles, where the silicate particle
surface area is not coated and hidden by the basically charged
glycoprotein, avidin. The observation of an increased inflam-
matory response for MSN-NH2 compared to MSN-AVI particles
suggests that the partially exposed silica surface of the
MSN-NH2 particles, but not the avidin protein covered surface,
induces inflammation. The MSN-NH2 particles have a large
BET surface area of 1150 m2 g−1 and a zeta potential of
−30 mV, while MSN-AVI particles have a BET surface area of
only 90 m2 g−1 and a zeta potential of 30 mV (measured at pH
= 7).6 This dramatic difference in accessible surface area and
charge indicates that the avidin protein covers the surface of
the MSN, thus significantly changing the surface character-
istics of the particles. Further analysis of the MSN’s incubated
with isolated mouse lung alveolar lining fluid (BALF) revealed
that MSN-NH2 particles form a significantly larger protein
corona compared to MSN-AVI particles (Fig. S3D†). This may
be explained by the partially exposed silica surface of the
MSN-NH2 particles, compared to the already protein-coated
MSN-AVI particles. This result highlights that MSN’s coated
with a protein corona do not behave similarly compared to
MSN particles that have a protein coat that is covalently
attached to the surface of the particle. Interestingly, when
instilling 100 µL of MSN-NH2 or non-functionalised MSNs
(with hydroxyl groups on the surface; nonMSN) into mice, we
observed that nonMSN cause significantly less acute inflam-
mation (pulmonary PMNs influx) compared to MSN-NH2 after
24 h (Table S1†). Both particles have a large BET surface area
arguing against surface area as major driver of toxicity in this
case. It is possible that the amine groups are responsible for
the increased inflammatory effect. Similarly, polystyrene par-
ticles with outer NH2 groups have been reported to be more
toxic then their hydroxyl counterparts.33–35 In addition to their
differential functionalities, our observations may also be
explained by the fact that MSN-NH2 particles form larger
agglomerates (about 1000 nm) compared to MSN-AVI and
nonMSN particles (about 200 nm) after only a few hours in sus-
pension (Fig. S3A†). Large agglomerates (bigger than 400 nm)
are more effectively phagocytized by macrophages than endo-
cytosed by epithelial cells.36 In addition, the formation of a
larger protein corona on MSN-NH2 particles compared to the
MSN-AVI (Fig. S3†) may also contribute to enhanced bio-
activity and even to the observed increased macrophage par-
ticle uptake for the MSN-NH2. Size-dependent nanoparticle
uptake has been observed previously in lung macrophage and
epithelial cells.37 All in all, our data suggests that avidin
protein modified MSNs are safe to use for lung application at
1 mg per kg dose and induce a minor inflammatory response
at 5 mg per kg dose that completely resolved after 7 days.
Cytotoxicity analysis
The toxic effects of the two particle types in the mouse model
were investigated with cytospins of bronchoalveolar lavage
(BAL) cells and on lung cryo-sections (from non-lavaged mice)
using immunofluorescence staining. For this approach, cells
and tissues were stained with an apoptotic cell marker
(cleaved caspase-3, green signal in Fig. 2A). The MSNs, co-
valently labelled with ATTO 633 dye, could easily be recognised
Table 1 Summary of the inflammatory effects of MSN-NH2 and MSN-AVI in BAL at 1, 3 and 7 days after instillation. In addition, an overview of the




count × 103 (%)
Macrophages cell
count × 103 (%)
Multinucleated macrophages
cell count × 103 (%) Detected cytokines
1 d HCCa — 0.2 (0) 280 (100) 0.1 (0) —
PBSb — 7.9 (1.6) 491 (98) 0.6 (0.1) —
MSN-AVI 20 9.2 (2) 444 (98) 0.1 (0) —
MSN-AVI 100 183 (33) 363 (66) 0.5 (0.1) CXCL5, CXCL1
MSN-NH2 100 326 (60) 131 (29) 0 (0) CXCL5, CXCL1, CCL2, IL-1β, TNF-α
3 d MSN-AVI 100 35 (5) 644 (95) 1.9 (0.3) CXCL5, CXCL1
MSN-NH2 100 65 (11) 511 (88) 3.4 (0.6) CXCL5, CXCL1, TNF-α
7 d MSN-AVI 100 2 (0.4) 581 (99) 0.9 (0.2) CXCL5
MSN-NH2 100 34 (4.3) 751 (95) 5.2 (0.7) CXCL5
aHCC = home cage control animals (non-treated mice). b PBS = 100 µL PBS instilled mice (vehicle/sham control).
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in both the cytospins and the cryo-sections (red signal in
Fig. 2A). Exposure to high doses of MSN-AVI particles did not
cause any significant apoptotic toxicity in BAL cells, compared
to the vehicle/sham control (PBS instilled mice) or the low
dose of MSN-AVI (Fig. 2A upper panel, controls are shown in
Fig. S4A†). Significant apoptosis, however, could be observed
for BAL cells exposed to MSN-NH2 particles, which did not
subside 7 days after exposure (Fig. 2A lower panel). Neither
particle type induced any distinguishable toxicity in lung cryo-
sections of the lavaged lungs (Fig. 2A, right panel). Further-
more, particle uptake and burden of the macrophages corre-
lated with increased apoptosis marker staining (Fig. 2B).
Macrophage MSN particle internalization was confirmed with
phalloidin staining in confocal microscopy, showing actin
(green) encapsulated MSN agglomerates (Fig. 2C). In addition,
in in vitro exposure experiments of the three major cell types of
Fig. 2 Cytotoxicity assessment of MSN-AVI and MSN-NH2 particles. (A) Toxicity of MSN-AVI or MSN-NH2 particles in Balb/c mice after instillation
with 100 µg for 1, 3, or 7 days, analyzed from cytospins of BAL cells (left) and lung cryo-slices (right). Cell nuclei are shown in blue (DAPI), ATTO 633
labelled MSNs are shown in red, and the apoptotic marker (cleaved caspase-3) is shown in green. (B) Toxicity of MSN-NH2 in Balb/c mice exposed to
100 µg for 7 days in cytospins of BAL recovered cells using a 63× objective; high particle loading correlates with toxicity. Yellow staining (in A and B)
is due to overlap of MSNs (red) and apoptotic cells (green). (C) MSN uptake in macrophages after 1 day exposure to, from left to right, 100 µL PBS,
100 µg MSN-AVI or MSN-NH2 (cytoskeleton labelled with phalloidin, green), (D) Cytotoxicity of MSN-AVI and MSN-NH2 particles as determined by
MTT assay in MH-S, MLE-12, and CCL-206 cells after 16 h of exposure. Values are indicated as mean ± SD, n = 3, asterisks represent significance
with *p < 0.05. Scale bar is 20 µm.
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the lung supported our in vivo observation; only MSN-NH2
showed significant cytotoxicity towards MH-S murine alveolar
macrophage cells, whereas no effect was observed in murine
lung epithelial (MLE-12) or fibroblast (CCL-206) cell lines at
high doses for either material (Fig. 2D). In line with that, also
no structural changes of the alveolar microarchitecture could
be observed in paraffin lung sections due to particle exposure
(Fig. S4B†). In accord with our pulmonary inflammation analy-
sis, the MSN-NH2 particles appear to cause selective macro-
phage toxicity, but no toxicity in lung parenchyma or in
epithelial and fibroblast cell lines. It seems therefore likely
that a phagocytic uptake of the large MSN-NH2 agglomerates is
required to generate the cytotoxic response while non-
professional phagocytes might be spared from the harmful
effects of non-avidin coated MSNs. In summary, the nano-
particle coating appears to be crucial for their inflammatory
and toxic response in the lung, where protein coating
enhances biocompatibility.
Pulmonary dose and clearance of MSNs
The pulmonary dose of MSN-AVI particles at the three time
points was determined by quantifying the fluorescent signal of
the particles in three pulmonary compartments, namely
homogenized lung tissue (after BAL), BAL fluid (BALF) and
BAL cells. Using gravimetric analysis of the instillation wear
prior and after instillation, we determined that 87.8 ± 3.5 µg
and 17.6 ± 0.6 µg of the nominally applied 100 µg and 20 µg
MSN dose was delivered to the lungs, respectively. It is impor-
tant to note that while the absolute pulmonary dose (in µg)
determines the toxicological (and pharmacological) response,
the pulmonary clearance (removal) and biodistribution of par-
ticles is typically expressed in terms of relative dose, i.e. pul-
monary dose normalized to applied dose (here: 87.8 or
17.6 µg). For the following, we refer to the pulmonary dose as
the relative dose. As seen in Fig. 3A, the pulmonary dose
slowly decreased from 80.1% of the applied dose at day 1 to
55.5% at day 7, indicating relatively slow clearance kinetics
(for both 20 and 100 µg MSN doses), which can be attributed
to macrophage clearance from the alveolar surface.36 By fitting
the measured total lung dose to an exponential function (rela-
tive dose = 0.851e−0.061t, where t represents time in units of
days), the alveolar clearance half time was determined as 8.7
days. During this period, the MSN dose decreased by 50%
corresponding to an average clearance rate of 5.7% per day.
Consequently, we found a relatively high retention of MSN-AVI
particles in pulmonary tissue at day 7 after instillation (56% of
the applied dose). When extrapolating the exponential fit curve
to t = 0 (time point of MSN application), one obtains a relative
dose of 0.851, i.e. macrophage clearance can only account for
85.1% of the actually applied dose. The residual 14.9% can be
attributed to a faster clearance mechanism known as mucocili-
ary clearance from the bronchial region, which is typically
completed within 1 d after application.36
The phagocytic clearance of MSNs was also studied on
cytospins of BAL cells by counting the amount of MSN agglom-
erates larger than 1 µm (the smallest detectable cross sectional
area) per nuclei on cytospins (i.e. the amount of >1 µm MSN
agglomerates over the total amount of counted nuclei per
image). After 1 day, more agglomerates of MSN-AVI could be
observed in the BAL compared to MSN-NH2 (Fig. 3C). The ratio
of estimated MSN agglomerates per nuclei showed a transient
increase at day 3 which declined again by day 7 after treatment
(Fig. 3D). The observed difference in clearance rate may be
explained by the fact that at day 1 the number of macrophages
in MSN-NH2 treated lungs had declined to about one third of
MSN-AVI treated mice due to the pronounced phagocyte toxi-
city of MSN-NH2. However, the macrophage number recovered
to similar levels of MSN-AVI treated mice at the later time
points (Fig. 1C).
Particle uptake specifically by alveolar macrophages was
confirmed, by counterstaining with a macrophage marker
(MAC3, green channel). All detected MSN-AVI were found in
macrophage marker positive cells with round nuclei, but not
in polymorphonuclear neutrophils, thus significant uptake by
other BAL cells could be excluded (Fig. 2E). The type A scaven-
ger receptor MARCO (macrophage receptor with collagenous
structure) has been described to function as an important
receptor of alveolar macrophages mediating the interaction
with unopsonized particles such as silica or bacteria.38 Since
the expression of MARCO is restricted to subpopulations of
tissue macrophages and particularly high in spleen marginal
zone, resident peritoneal, and alveolar macrophages but is low
in monocyte derived macrophages,39 the choice of cells
studied is very important. Surface modification, such as by
avidin might reduce the interaction of MSN particles with
these scavenger receptors and thus effect a rapid phagocytosis
and related clearance by alveolar macrophages. In summary,
MSN-AVI particles showed the bimodal lung clearance kinetics
(i.e. slow alveolar macrophage clearance, and fast mucociliary
clearance from the bronchial region) which is typical for par-
ticle removal from the lungs.36 The MSN-AVI had a slow clear-
ance kinetics which is particularly promising for pulmonary
therapy as it increases the residence time and hence the bio-
availability of the encapsulated drugs.
Particle distribution in the lung
The distribution of MSNs in the lungs was assessed by prepar-
ing cryo-sections of (non-lavaged) lungs, which were analysed
by immunofluorescence. ATTO 633 labelled MSNs could easily
be detected by confocal microscopy on 14 µm thick lung cryo-
sections (red channel, Fig. 4A). The MSNs were distributed
evenly over the tissue, also reaching the alveolar region of the
lung. Furthermore, the nanoparticles showed widespread and
significant accumulation in the lungs for at least 7 days, con-
firming our previous dosimetry findings (Fig. 4A and S5†).
After 1 day, many particle agglomerates could be observed,
while after 3 and 7 days, fewer but bigger MSN-AVI agglomer-
ates remained (Fig. 4A lower panel). High magnification
images indicated that a fraction of the MSN-AVI particles
remained on the epithelium, evidence of which was still
present after 7 days (Fig. 4B and S5†). In contrast, only limited
evidence was obtained that MSN-NH2 particles were taken up
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by epithelial cells. In fact, when investigating cryo-sections at
higher magnifications, we mainly observed macrophage
uptake of MSN-NH2 particles (Fig. 4C). Furthermore, z-stack
images of non-phagocytized MSN-NH2 particles revealed that
these nanoparticles appear to associate with the tissue rather
than being internalized into the cells (Fig. 4C, right panel).
Counterstaining the cryo-sections with epithelial type I and II
cell markers, podoplanin (T1α) and pro-surfactant associated
protein C (Pro-SPC), respectively, revealed that MSN-AVI par-
ticles are internalized by epithelial lung cells (Fig. 4D, E and
S4†) as confirmed by confocal z-stack imaging (Fig. 5A). To
investigate the cell specific uptake further, we prepared co-
cultures of a murine alveolar macrophage cell line (MH-S) and
an alveolar epithelial cell line (MLE-12) to study the fate of the
particles in an in vitro model. Clearly distinguishable cell
populations could be observed by fluorescence-activated cell
sorting (FACS) analysis excluding leakage of the dye to the
other cell type at the studied time-points (Fig. S7†). Co-cultures
indeed showed enhanced MSN-AVI particle uptake in epithelial
cells compared to macrophage cell uptake (Fig. 5B, left panel).
In contrast, MSN-NH2 particles showed almost exclusively
uptake in macrophages in the same co-culture set-up (Fig. 5B,
right panel).
In summary, cell type specific immunostainings revealed
that MSN-NH2 particles are preferentially internalized by
macrophages in vivo and in vitro and that this leads to macro-
phage cytotoxicity. In contrast, MSN-AVI particles were – in
addition to being phagocytically cleared by macrophages –
also efficiently internalized by alveolar epithelial type 1 and
type 2 cells, as investigated in lung tissue cryo-sections. More-
Fig. 3 Pulmonary dose and clearance of MSNs in the lungs of Balb/c mice up to seven days after particle instillation. (A) Temporal decrease of pul-
monary dose (normalized to applied dose) and derived exponential clearance kinetics of MSN-AVI particles up to day 7 (n = 3). (B) MSN-AVI particle
distribution in lung tissue and BAL over time (n = 3). (C) MSN-AVI and MSN-NH2 particles (red) distribution in BAL cells (nuclei DAPI staining, blue)
after 1 day. (D) Quantification of particle clearance in BAL cells depicted as the number of MSN agglomerates (larger than 1 µm) per counted nuclei
(n = 3 animals, 2 images per animal). (E) MSN-AVI particles (red) in BAL recovered cells with macrophage marker co-staining (MAC3, green). Cell
nuclei are shown in blue (DAPI), ATTO 633 labelled MSNs are shown in red. Scale bar is 20 µm.
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over, MSN-AVI also showed higher uptake in epithelial cells
compared to macrophage cell uptake in an in vitro co-culture
model. Previous studies have shown that cellular uptake of
MSNs is highly dependent on surface charge, surface modifi-
cations, and is cell type-specific.40,41 Furthermore, several
in vitro studies have shown that the cell uptake of MSNs is cell-
type-, dosage- and time-dependent.42,43 Interestingly, it has
been reported that amination of MSN particles prevents par-
ticle endocytosis in T-lymphocyte cells (Jurkat) and in a
human neuroblast cell line.36,41 These findings highlight the
Fig. 4 MSN distribution in mouse lungs up to 7 days after particle instillation. (A) Lung cryo-slices of Balb/c mice exposed to 100 µg MSN-AVI for 1,
3, or 7 days with phalloidin co-staining (upper panel) and the same images showing only MSNs (lower panel, MSNs are shown in white to increase
the contrast). Lung cryo-slices of Balb/c mice exposed to (B) 100 µg MSN-AVI for 1 day (left) and 7 days (right)(arrowheads represent locations of
MSN-AVI) and (C) 100 µg MSN-NH2 for 1 day, (D) 100 µg MSN-AVI with epithelial cell type 1 co-staining (T1α, green) for 1 day (left) and 7 days (right),
and (E) 100 µg MSN-AVI with epithelial cell type 2 co-staining (pro-SPC, green) for 1 day (left) and 7 days (right). Cell nuclei are shown in blue (DAPI),
ATTO 633 labelled MSNs are shown in red. Images are representative images for n = 4 animals. Scale bar is 20 µm.
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importance of outer surface modifications and their inter-
actions with different cell types, but also that avidin coating
may be a good strategy to overcome issues related to macro-
phage uptake and particle toxicity.
Conclusions
In this study, we investigated the relevance of avidin-capped
MSNs (MSN-AVI) for pulmonary therapy by looking at their pul-
monary distribution, clearance rate, cell specific uptake, and
induction of inflammatory response after direct (intratracheal)
instillation in the lungs of mice. In a recent publication we
showed that these particles are promising carriers for lung
cancer therapy as they could release a combination of drugs
efficiently and tumor-selectively in in vitro and in human and
mouse ex vivo lung tissue.6 Since MSNs allow for multiple
functionalizations, which have been found to be important for
their bioresponse, we also included non-capped (only amino-
functionalized; MSN-NH2) particles in this study. We show that
MSN avidin surface modification had an effect not only on
toxicity, but also on cell specific uptake and tissue distribution
in the lungs. In particular, non-capped (MSN-NH2) particles
were found to be cytotoxic to macrophages, caused an
enhanced inflammatory response, and were hardly taken up
by epithelial cells. In contrast, MSN-AVI particles co-localized
with alveolar epithelial type 1 and type 2 cells in the lung
tissue and showed preferential epithelial cell uptake in in vitro
co-cultures. These findings, in combination with the low
surface specific toxicity, wide distribution of the particles in
the mouse lungs and slow clearance rate is promising for the
treatment of chronic lung diseases such as COPD, IPF, and
lung cancer, where (alveolar) epithelial cells play an important
role in the pathogenesis. Moreover, the inflammatory potential
of drug delivery particles is most critical in inflammatory lung
diseases such as asthma and COPD, due to additive effects
leading to worsening of the symptoms. In this context, the
observation that the dose of 1 mg kg−1 of MSN-AVI did not
cause any detectable inflammatory response is particularly
promising for treatment of these devastating lung diseases.
Thus, we believe that avidin-coated MSNs offer potential for
inhalative application as therapeutic drug carriers in chronic
lung diseases. In addition, the finding that surface modifi-
cations greatly affect toxicity and cell type specific uptake high-
lights the importance of these types of studies for future
development of nanomedicines.
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